Talk to us today to advertise here : : ( 02 ) 8484 0732 OR GPClassifieds sales @ ausdocjobs @ adg . com . . au .
59
JOB OF THE WEEK
FT PT | VR GP | MIXED BILLING | 75 % OF BILLINGS | WALLAN , VIC
• Busy , well established clinic of 20 + years
• Supportive and friendly environment
• Full-time Nurse support
• Pathology onsite
• Dedicated Treatment Room
• No after-hours required
BUILD THE CAREER YOU WANT
AusDoc . JOBS
• Built specifically for GPs
• From Australia ’ s # 1 GP medical publication
• Immediate start
Interested ? Contact Julie - Practice Manager
P : 03 5783 1522 E : julie . b @ wallanfamilypractice . com . au
Find your next job at ausdocjobs . com . au
NEW SOUTH WALES |
|
|
|
GP WANTED
Existing patient base in Byron Bay
We have a fantastic opportunity for a GP to hit the ground running in a fully accredited GP and Skin Cancer Clinic in Byron Bay .
Access an instant full patient base and enjoy the flexibility The Bright Side Clinic has to offer .
Flexible working hours and days Highly trained , supportive nurse and admin team DPA location Only 40 minutes from the Gold Coast
Contact Sharon Magro 0408 518 192 sharon @ skincancercentres . com . au
thebrightsideclinic . com . au
|
CHATSWOOD
FT VR GP The Practice was established in 1980 ’ s . The Practice provides comprehensive and personalized health care services in one convenient location close to the station .
• Telehealth / Phone and face to face consultations available
• Full time Position vacant
• No lock in contracts
• Clinic Hours Monday to Friday 7:30am to 5:00pm
• Possibilities of weekends as well
• Flexible with days , times and leave
• Excellent Remuneration 75 %
• Looking for GP ’ s who are motivated and would like to establish themselves
• Non-Corporate , Doctor owned , collegial and supported by full-time nurse and pathology onsite
P : 02 9411 7916
|
|
|
INNER WOLLONGONG SUBURB GP WANTED
• Private and bulk-billing accredited General Practice
• Long established ( over 50 years )
• 4 doctor private practice with huge patient base
• Well-reputationed and sought after by patients
• Friendly efficient staff , practice nurse , modern facilities
• No after hours , 1 in 4 Sat am only
• Principal retiring after 37 years
• Can trial on percentage basis with view to associateship
|
P : 0432313736 |
|
SUTHERLAND SHIRE - ENGADINE 2233
FT VR GP
• Full time position to take over an existing patient base
• Busy practice , AGPAL accredited
• Nurses and pathology on site , on-site parking
• Own dedicated consultation room
• 40 % private billings
• Days worked and annual leave negotiable / flexible
• Privately owned , friendly enviroment
P : 9520 2382 M : 0418 410 221 E : givayr @ pip . com . au
|
PALEXIA ® PRIMARY ADVERTISEMENT
PAIN MANAGEMENT RESOURCES ON DEMAND
www . PALEXIA . com . au
PALEXIA . com . au is a dedicated website for Australian Healthcare Professionals , where you can access educational video content and other resources , including information for patients . Scan the QR code to register .
PBS Information : PALEXIA ® IR : This product is not listed on the PBS . PALEXIA ® SR : Authority Required ( STREAMLINED ). Refer to PBS schedule for full authority information .
BOXED WARNING : PALEXIA ® should be limited to patients for whom other treatment options are ineffective , not tolerated or otherwise inadequate . There are risks of hazardous and harmful use leading to overdose and death ; life-threatening respiratory depression ; and profound sedation , respiratory depression , coma and death resulting from concomitant use with benzodiazepines , alcohol and other CNS depressants . See Boxed Warning in full Product Information for further details .
Before prescribing , please review Product Information available at www . seqirus . com . au / products
MINIMUM PRODUCT INFORMATION : PALEXIA ® ( tapentadol hydrochloride ) INDICATION : PALEXIA ® IR For the short-term management of severe pain for which other treatment options have failed , are contraindicated , not tolerated or are otherwise inappropriate to provide sufficient management of pain . PALEXIA ® SR For the management of severe pain where other treatment options have failed , are contraindicated , not tolerated or are otherwise inappropriate to provide sufficient management of pain , and the pain is opioid-responsive , and requires daily , continuous , long-term treatment . Not indicated for use in chronic non-cancer pain other than in exceptional circumstances or as PRN analgesia . CONTRAINDICATIONS : Known hypersensitivity to tapentadol or any component of PALEXIA ® IR / SR ( contains lactose ); severe or acute respiratory disease or respiratory depression ; confirmed or suspected paralytic ileus ; acute intoxication with alcohol , hypnotics , centrally acting analgesics or psychotropic drugs ; patients who are receiving MAO inhibitors or who have taken them within the last 14 days . PRECAUTIONS : Risk of abuse , misuse , addiction , tolerance , dependence and withdrawal – monitor for signs / symptoms , taper gradually to avoid abrupt cessation ; risk of life-threatening respiratory depression , accidental ingestion / exposure and hyperalgesia ; risks from concomitant use with benzodiazepines , alcohol and other CNS depressants ; not recommended in chronic non-cancer pain , in patients with increased intracranial pressure , impaired consciousness , coma or severe renal or severe hepatic impairment ; caution in patients with sleep-related breathing disorders , head injury , brain tumours , a history of seizures or any condition that increases risk of seizures , moderate hepatic impairment or biliary tract disease , including acute pancreatitis . May impair ability to drive or operate machinery . Use in pregnancy ( Category C ). Should not be used during breastfeeding . Not recommended for children < 18 years old . INTERACTIONS : Take care when combining with other opioid agents ; additive CNS depression with concomitant administration of other mu-opioid receptor agonist analgesics , general anaesthetics , phenothiazines , other tranquilisers , sedatives , hypnotics or other CNS depressants ( including alcohol and illicit drugs ); isolated case reports of serotonin syndrome when used in combination with serotoninergic drugs . ADVERSE EFFECTS : PALEXIA ® IR Very common ( ≥1 / 10 ): dizziness , somnolence , headache , nausea , vomiting ; Common ( ≥1 / 100 to < 1 / 10 ): Decreased appetite , anxiety , confusional state , hallucination , sleep disorder , abnormal dreams , tremor , flushing , constipation , diarrhoea , dyspepsia , dry mouth , pruritus , hyperhidrosis , rash , muscle spasms , asthenia , fatigue , feeling of body temperature change . PALEXIA ® SR Very common ( ≥1 / 10 ): dizziness , somnolence , headache , nausea , constipation ; Common ( ≥1 / 100 to < 1 / 10 ): Decreased appetite , anxiety , depressed mood , sleep disorder , nervousness , restlessness , disturbance in attention , tremor , muscle contractions involuntary , flushing , dyspnoea , vomiting , diarrhoea , dyspepsia , pruritus , hyperhidrosis , rash , asthenia , fatigue , feeling of body temperature change , mucosal dryness , oedema . DOSAGE AND ADMINISTRATION : PALEXIA ® IR Take whole tablet , orally , approximately every 4 to 6 hours , with or without food . Usual recommended dose 50 to 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability . Total daily doses > 600 mg not recommended . PALEXIA ® SR Take whole tablet , orally , approximately every twelve hours , with or without food . Initiation : in patients currently not taking opioid analgesics , start with 50 mg twice daily ; in patients currently taking opioid analgesics , the nature , administration and mean daily dose of previous medication should be taken into account . Total daily doses > 500 mg not recommended . Titration and maintenance : titrate individually to a level that provides adequate analgesia and minimises side effects . Discontinuation : taper dose gradually to prevent symptoms of withdrawal . Special populations : Not recommended in severe renal or severe hepatic impairment . PALEXIA ® IR initiate at 50mg every 8 hours ( maximum three doses in 24 hours ) in moderate hepatic impairment . PALEXIA ® SR initiate with caution at 50mg once daily in moderate hepatic impairment . Use care in dose selection for elderly patients ( likely decreased renal and hepatic function ). Based on approved Product Information .
PALEXIA ® is registered trademark of Grünenthal Pty Ltd and distributed by Seqirus ( Australia ) Pty Ltd under licence from Grünenthal Pty Ltd . Seqirus ( Australia ) Pty Ltd ABN 66 120 398 067 , Tower 1 , Level 12 Collins Square , 727 Collins Street , Melbourne VIC 3008 . www . seqirus . com . au . Medical Information : 1800 642 865 . Seqirus™ is a trademark of Seqirus UK Limited or its affiliates . Date of preparation : March 2022 . ANZ-PALX-22-0029
ANZ-PALX-21-0220 . 001095 .
001095 Palexia 2022 advert - PRINT - A3 ADG _ 280x400 &_ 1-3rd _ v12 _ 01 FA . indd 2 24 / 3 / 22 11:59 am